Tags

Type your tag names separated by a space and hit enter

Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
J Clin Neurosci. 2011 Aug; 18(8):1093-6.JC

Abstract

Parkinson's disease (PD) is characterized by progressive degeneration of melanin-containing neurons in the substantia nigra pars compacta (SNc). Pathological change has not been detected by neuroimaging techniques in patients with PD in vivo. We examined 80 patients with PD to determine whether degeneration of the SNc is detectable in vivo by MRI. The age-matched controls consisted of 54 patients who had suffered mild acute ischemic stroke. Axial T1-weighted MRI were obtained with a 3-Tesla MRI scanner. The border of the neuromelanin-sensitive region in the SNc was traced manually on these images, and the volume of this area was calculated. The mean volumes for the left and right SNc were significantly reduced in patients with PD compared to the controls. Volume loss became marked in parallel with disease severity and duration. Neuromelanin MRI may be considered as a biomarker of nigral degeneration in patients with PD.

Authors+Show Affiliations

Department of Neurology, Okayama Kyokuto Hospital, 567-1 Kurata, Naka-ku, Okayama 703-8265, Japan. kkashi@kyokuto.or.jpNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21719292

Citation

Kashihara, Kenichi, et al. "Neuromelanin Magnetic Resonance Imaging of Nigral Volume Loss in Patients With Parkinson's Disease." Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, vol. 18, no. 8, 2011, pp. 1093-6.
Kashihara K, Shinya T, Higaki F. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci. 2011;18(8):1093-6.
Kashihara, K., Shinya, T., & Higaki, F. (2011). Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, 18(8), 1093-6. https://doi.org/10.1016/j.jocn.2010.08.043
Kashihara K, Shinya T, Higaki F. Neuromelanin Magnetic Resonance Imaging of Nigral Volume Loss in Patients With Parkinson's Disease. J Clin Neurosci. 2011;18(8):1093-6. PubMed PMID: 21719292.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. AU - Kashihara,Kenichi, AU - Shinya,Takayoshi, AU - Higaki,Fumiyo, Y1 - 2011/06/29/ PY - 2009/10/20/received PY - 2010/04/04/revised PY - 2010/08/07/accepted PY - 2011/7/2/entrez PY - 2011/7/2/pubmed PY - 2011/12/13/medline SP - 1093 EP - 6 JF - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia JO - J Clin Neurosci VL - 18 IS - 8 N2 - Parkinson's disease (PD) is characterized by progressive degeneration of melanin-containing neurons in the substantia nigra pars compacta (SNc). Pathological change has not been detected by neuroimaging techniques in patients with PD in vivo. We examined 80 patients with PD to determine whether degeneration of the SNc is detectable in vivo by MRI. The age-matched controls consisted of 54 patients who had suffered mild acute ischemic stroke. Axial T1-weighted MRI were obtained with a 3-Tesla MRI scanner. The border of the neuromelanin-sensitive region in the SNc was traced manually on these images, and the volume of this area was calculated. The mean volumes for the left and right SNc were significantly reduced in patients with PD compared to the controls. Volume loss became marked in parallel with disease severity and duration. Neuromelanin MRI may be considered as a biomarker of nigral degeneration in patients with PD. SN - 1532-2653 UR - https://www.unboundmedicine.com/medline/citation/21719292/Neuromelanin_magnetic_resonance_imaging_of_nigral_volume_loss_in_patients_with_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0967-5868(11)00122-6 DB - PRIME DP - Unbound Medicine ER -